Kidney Disease: Improving Global Outcomes CKD Work Group: KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int105: S117–S314, 2024PubMed
Kidney Disease: Improving Global Outcomes CKD Work Group: KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 105: S117–S314, 2024PubMed)| false
LuyckxVA, TuttleKR, AbdellatifD, Correa-RotterR, FungWWS, HarisA, et al.; World Kidney Day Joint Steering Committee: Mind the gap in kidney care: Translating what we know into what we do. Kidney Int105: 406–417, 2024PubMed
LuyckxVA, TuttleKR, AbdellatifD, Correa-RotterR, FungWWS, HarisA, ; World Kidney Day Joint Steering Committee: Mind the gap in kidney care: Translating what we know into what we do. Kidney Int 105: 406–417, 2024PubMed)| false
FengX, HouN, ChenZ, LiuJ, LiX, SunX, et al.: Secular trends of epidemiologic patterns of chronic kidney disease over three decades: An updated analysis of the Global Burden of Disease Study 2019. BMJ Open13: e064540, 2023PubMed
FengX, HouN, ChenZ, LiuJ, LiX, SunX, : Secular trends of epidemiologic patterns of chronic kidney disease over three decades: An updated analysis of the Global Burden of Disease Study 2019. BMJ Open 13: e064540, 2023PubMed)| false
Nuffield Department of Population Health Renal Studies Group. SGLT Inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium: Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: Collaborative meta-analysis of large placebo controlled trials. Lancet400: 1788–1801, 2022PubMed
Nuffield Department of Population Health Renal Studies Group. SGLT Inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium: Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: Collaborative meta-analysis of large placebo controlled trials. Lancet 400: 1788–1801, 2022PubMed)| false
National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis39: S1–S266, 2002PubMed
National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 39: S1–S266, 2002PubMed)| false
Kidney Disease: Improving Global Outcomes CKD Work Group: KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl3: S1–S150, 2012
Kidney Disease: Improving Global Outcomes CKD Work Group: KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3: S1–S150, 2012)| false
PerkovicV, JardineMJ, NealB, BompointS, HeerspinkHJL, CharytanDM, et al.; CREDENCE Trial Investigators: Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med380: 2295–2306, 2019PubMed
PerkovicV, JardineMJ, NealB, BompointS, HeerspinkHJL, CharytanDM, ; CREDENCE Trial Investigators: Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380: 2295–2306, 2019PubMed)| false
HerringtonWG, StaplinN, WannerC, GreenJB, HauskeSJ, EmbersonJR, et al.; The EMPA-KIDNEY Collaborative Group: Empagliflozin in patients with chronic kidney disease. N Engl J Med388: 117–127, 2023PubMed
AgarwalR, FilippatosG, PittB, AnkerSD, RossingP, JosephA, et al.; FIDELIO-DKD and FIGARO-DKD investigators: Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: The FIDELITY pooled analysis. Eur Heart J43: 474–484, 2022PubMed
AgarwalR, FilippatosG, PittB, AnkerSD, RossingP, JosephA, ; FIDELIO-DKD and FIGARO-DKD investigators: Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: The FIDELITY pooled analysis. Eur Heart J 43: 474–484, 2022PubMed)| false
ColombijnJMT, IdemaDL, van BeemS, BloklandAM, van der BraakK, HandokoML, et al.: Representation of patients with chronic kidney disease in clinical trials of cardiovascular disease medications: A systematic review. JAMA Netw Open7: e240427, 2024PubMed
ColombijnJMT, IdemaDL, van BeemS, BloklandAM, van der BraakK, HandokoML, : Representation of patients with chronic kidney disease in clinical trials of cardiovascular disease medications: A systematic review. JAMA Netw Open 7: e240427, 2024PubMed)| false
HussainJ, GrubicN, AkbariA, CanneyM, ElliottMJ, RavaniP, et al.: Associations between modest reductions in kidney function and adverse outcomes in young adults: Retrospective, population based cohort study. BMJ381: e075062, 2023PubMed
HussainJ, GrubicN, AkbariA, CanneyM, ElliottMJ, RavaniP, : Associations between modest reductions in kidney function and adverse outcomes in young adults: Retrospective, population based cohort study. BMJ 381: e075062, 2023PubMed)| false
GramsME, CoreshJ, MatsushitaK, BallewSH, SangY, SurapaneniA, et al.; Writing Group for the CKD Prognosis Consortium: Estimated glomerular filtration rate, albuminuria, and adverse outcomes: An individual-participant data meta-analysis. JAMA330: 1266–1277, 2023PubMed
ShlipakMG, TummalapalliSL, BoulwareLE, GramsME, IxJH, JhaV, et al.; Conference Participants: The case for early identification and intervention of chronic kidney disease: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int99: 34–47, PubMed
ShlipakMG, TummalapalliSL, BoulwareLE, GramsME, IxJH, JhaV, ; Conference Participants: The case for early identification and intervention of chronic kidney disease: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 99: 34–47, PubMed)| false
RoweC, SitchAJ, BarrattJ, BrettellEA, CockwellP, DaltonRN, et al.; eGFR-C Study Group: Biological variation of measured and estimated glomerular filtration rate in patients with chronic kidney disease. Kidney Int96: 429–435, 2019PubMed
TangriN, StevensLA, GriffithJ, TighiouartH, DjurdjevO, NaimarkD, et al.: A predictive model for progression of chronic kidney disease to kidney failure. JAMA305: 1553–1559, 2011PubMed
TangriN, StevensLA, GriffithJ, TighiouartH, DjurdjevO, NaimarkD, : A predictive model for progression of chronic kidney disease to kidney failure. JAMA 305: 1553–1559, 2011PubMed)| false
TangriN, KitsiosGD, InkerLA, GriffithJ, NaimarkDM, WalkerS, et al.: Risk prediction models for patients with chronic kidney disease: A systematic review. Ann Intern Med158: 596–603, 2013PubMed
TangriN, GramsME, LeveyAS, CoreshJ, AppelLJ, AstorBC, et al.; CKD Prognosis Consortium: Multinational assessment of accuracy of equations for predicting risk of kidney failure a meta-analysis. JAMA315: 164–174, 2016PubMed
RamspekCL, de JongY, DekkerFW, van DiepenM: Towards the best kidney failure prediction tool: A systematic review and selection aid. Nephrol Dial Transplant35: 1527–1538, 2020PubMed
RamspekCL, de JongY, DekkerFW, van DiepenM: Towards the best kidney failure prediction tool: A systematic review and selection aid. Nephrol Dial Transplant 35: 1527–1538, 2020PubMed)| false
National Institute for Health and Care Excellence: Evidence Review for the Best Combination of Measures to Identify Increased Risk of Progression in Adults, Children and Young People: Chronic Kidney Disease, NICE, 2021
National Institute for Health and Care Excellence: Evidence Review for the Best Combination of Measures to Identify Increased Risk of Progression in Adults, Children and Young People: Chronic Kidney Disease, NICE, 2021)| false
GramsME, BrunskillNJ, BallewSH, SangY, CoreshJ, MatsushitaK, et al.; CKD Prognosis Consortium: Development and validation of prediction models of adverse kidney outcomes in the population with and without diabetes. Diabetes Care45: 2055–2063, 2022PubMed
GramsME, BrunskillNJ, BallewSH, SangY, CoreshJ, MatsushitaK, ; CKD Prognosis Consortium: Development and validation of prediction models of adverse kidney outcomes in the population with and without diabetes. Diabetes Care 45: 2055–2063, 2022PubMed)| false
Hippisley-CoxJ, CouplandC, BrindleP: Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: Prospective cohort study. BMJ357: j2099, 2017PubMed
MatsushitaK, JassalSK, SangY, BallewSH, GramsME, SurapaneniA, et al.: Incorporating kidney disease measures into cardiovascular risk prediction: Development and validation in 9 million adults from 72 datasets. EClinicalMedicine27: 100552, 2020PubMed
MatsushitaK, JassalSK, SangY, BallewSH, GramsME, SurapaneniA, : Incorporating kidney disease measures into cardiovascular risk prediction: Development and validation in 9 million adults from 72 datasets. EClinicalMedicine 27: 100552, 2020PubMed)| false
KhanSS, CoreshJ, PencinaMJ, NdumeleCE, RangaswamiJ, ChowSL, et al.; American Heart Association: Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: A scientific statement from the American Heart Association. Circulation148: 1982–2004, 2023PubMed
KhanSS, CoreshJ, PencinaMJ, NdumeleCE, RangaswamiJ, ChowSL, ; American Heart Association: Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: A scientific statement from the American Heart Association. Circulation 148: 1982–2004, 2023PubMed)| false
KhanSS, MatsushitaK, SangY, BallewSH, GramsME, SurapaneniA, et al.; Chronic Kidney Disease Prognosis Consortium and the American Heart Association Cardiovascular-Kidney-Metabolic Science Advisory Group: Development and validation of the American Heart Association’s PREVENT equations. Circulation149: 430–449, 2024PubMed
KhanSS, MatsushitaK, SangY, BallewSH, GramsME, SurapaneniA, ; Chronic Kidney Disease Prognosis Consortium and the American Heart Association Cardiovascular-Kidney-Metabolic Science Advisory Group: Development and validation of the American Heart Association’s PREVENT equations. Circulation 149: 430–449, 2024PubMed)| false
AtiquzzamanM, ZhuB, RomannA, ErL, DjurdjevO, BevilacquaM, et al.: Kidney Failure Risk Equation in vascular access planning: A population-based study supporting value in decision making. Clin Kidney J17: sfae008, 2024PubMed
Marques da SilvaB, DoresM, SilvaO, PereiraM, OutereloC, FortesA, et al.: Planning vascular access creation: The promising role of the kidney failure risk equation. J Vasc Access11297298231186373, 2023PubMed
LundströmUH, RamspekCL, DekkerFW, van DiepenM, CarreroJJ, HedinU, et al.: Clinical impact of the Kidney Failure Risk Equation for vascular access planning [published online ahead of print Mar 14, 2024]. Nephrol Dial Transplant10.1093/ndt/gfae064PubMed
LiuP, SawhneyS, Heide-JørgensenU, QuinnRR, JensenSK, McleanA, et al.: Predicting the risks of kidney failure and death in adults with moderate to severe chronic kidney disease: Multinational, longitudinal, population based, cohort study. BMJ385: e078063,2024PubMed
LiuP, SawhneyS, Heide-JørgensenU, QuinnRR, JensenSK, McleanA, : Predicting the risks of kidney failure and death in adults with moderate to severe chronic kidney disease: Multinational, longitudinal, population based, cohort study. BMJ 385: e078063,2024PubMed)| false
KellyJT, SuG, ZhangL, QinX, MarshallS, González-OrtizA, et al.: Modifiable lifestyle factors for primary prevention of CKD: A systematic review and meta-analysis. J Am Soc Nephrol32: 239–253, 2021PubMed
Bernier-JeanA, PrinceRL, LewisJR, CraigJC, HodgsonJM, LimWH, et al.: Dietary plant and animal protein intake and decline in estimated glomerular filtration rate among elderly women: A 10-year longitudinal cohort study. Nephrol Dial Transplant36: 1640–1647, 2021PubMed
Kidney Disease: Improving Global Outcomes Blood Pressure Work Group: KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int99: S1–S87, 2021PubMed
Kidney Disease: Improving Global Outcomes Blood Pressure Work Group: KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int 99: S1–S87, 2021PubMed)| false
ParkCH, KimHW, JooYS, ParkJT, ChangTI, YooT-H, et al.; KNOW-CKD (KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease) Investigators: Findings from the KNOW-CKD Study indicate that higher systolic blood pressure time in target range is associated with a lower risk of chronic kidney disease progression. Kidney Int105: 835–843, 2024PubMed
ParkCH, KimHW, JooYS, ParkJT, ChangTI, YooT-H, ; KNOW-CKD (KoreaN Cohort Study for Outcomes in Patients With Chronic Kidney Disease) Investigators: Findings from the KNOW-CKD Study indicate that higher systolic blood pressure time in target range is associated with a lower risk of chronic kidney disease progression. Kidney Int 105: 835–843, 2024PubMed)| false
XieX, LiuY, PerkovicV, LiX, NinomiyaT, HouW, et al.: Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: A Bayesian network meta-analysis of randomized clinical trials. Am J Kidney Dis67: 728–741, 2016PubMed
XieX, LiuY, PerkovicV, LiX, NinomiyaT, HouW, : Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: A Bayesian network meta-analysis of randomized clinical trials. Am J Kidney Dis 67: 728–741, 2016PubMed)| false
JafarTH, SchmidCH, LandaM, GiatrasI, TotoR, RemuzziG, et al.: Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data [published erratum appears in Ann Intern Med 137: 299, 2002]. Ann Intern Med135: 73–87, 2001PubMed
JafarTH, SchmidCH, LandaM, GiatrasI, TotoR, RemuzziG, : Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data [published erratum appears in Ann Intern Med 137: 299, 2002]. Ann Intern Med 135: 73–87, 2001PubMed)| false
KandaE, RastogiA, MuroharaT, LesénE, AgiroA, ArnoldM, et al.: Clinical impact of suboptimal RAASi therapy following an episode of hyperkalemia. BMC Nephrol24: 18,2023PubMed
QiaoY, ShinJ-I, ChenTK, InkerLA, CoreshJ, AlexanderGC, et al.: Association between renin-angiotensin system blockade discontinuation and all-cause mortality among persons with low estimated glomerular filtration rate. JAMA Intern Med180: 718–726, 2020PubMed
QiaoY, ShinJ-I, ChenTK, InkerLA, CoreshJ, AlexanderGC, : Association between renin-angiotensin system blockade discontinuation and all-cause mortality among persons with low estimated glomerular filtration rate. JAMA Intern Med 180: 718–726, 2020PubMed)| false
FuEL, EvansM, ClaseCM, TomlinsonLA, van DiepenM, DekkerFW, et al.: Stopping renin-angiotensin system inhibitors in patients with advanced CKD and risk of adverse outcomes: A nationwide study. J Am Soc Nephrol32: 424–435, 2021PubMed
FuEL, EvansM, ClaseCM, TomlinsonLA, van DiepenM, DekkerFW, : Stopping renin-angiotensin system inhibitors in patients with advanced CKD and risk of adverse outcomes: A nationwide study. J Am Soc Nephrol 32: 424–435, 2021PubMed)| false
HumphreyTJL, JamesG, WittbrodtET, ZarzuelaD, HiemstraTF: Adverse clinical outcomes associated with RAAS inhibitor discontinuation: Analysis of over 400000 patients from the UK Clinical Practice Research Datalink (CPRD). Clin Kidney J14: 2203–2212, 2021PubMed
HumphreyTJL, JamesG, WittbrodtET, ZarzuelaD, HiemstraTF: Adverse clinical outcomes associated with RAAS inhibitor discontinuation: Analysis of over 400000 patients from the UK Clinical Practice Research Datalink (CPRD). Clin Kidney J 14: 2203–2212, 2021PubMed)| false
FletcherBR, DameryS, AiyegbusiOL, AndersonN, CalvertM, CockwellP, et al.: Symptom burden and health-related quality of life in chronic kidney disease: A global systematic review and meta-analysis. PLoS Med19: e1003954, 2022PubMed
FletcherBR, DameryS, AiyegbusiOL, AndersonN, CalvertM, CockwellP, : Symptom burden and health-related quality of life in chronic kidney disease: A global systematic review and meta-analysis. PLoS Med 19: e1003954, 2022PubMed)| false
BarracloughKA, MollerS, BlairS, KnightR, AgarJW, McAlisterS, et al.: Updating the data: The resource consumption of modern-day hemodialysis systems. Kidney Int Rep9: 1521–1524, 2024PubMed